FDA Brief

Warning letters Food

FDA warning letter to

Eniva USA, Inc.

MediumIssued Sep 10, 2025Posted Feb 3Human Foods Program

FDA warns Eniva USA over manufacturing quality failures for Immune Support and Ashwagandha Gummies.

What happened

FDA inspected Eniva USA's Plymouth, MN facility from November 19, 2024, through January 13, 2025, and reviewed product labels and the website. FDA found the firm did not establish finished-product specifications for identity, purity, strength, and composition and did not document material review and disposition decisions. FDA also said the firm's response on acid foods under 21 CFR 114.83 was inadequate.

What FDA found

  1. Eniva USA did not establish finished-batch specifications that confirm the identity, purity, strength, and composition of its Immune Support and Ashwagandha Gummies supplements.

    21 CFR 111.70(e)
  2. Eniva USA did not document investigations, findings, quality review, and disposition decisions for material review events.

    21 CFR 111.140(b)(3)
  3. FDA found the firm's response about whether Vibe products are acid foods inadequate and asked for supporting documents, formulation, and pH information.

    21 CFR 114.83

What FDA wants

FDA asks Eniva USA to notify it in writing within 15 working days of steps taken to address the violations, with explanations and documentation to prevent recurrence. If corrections cannot be completed in that time, the firm must state why and give a completion timeframe.

Who should pay attention

  • dietary supplement manufacturers with similar finished-product specifications
  • quality teams responsible for material review and disposition records
  • brands selling acidified or acid-food beverages like Vibe

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk